Mepolizumab clinical trials
Also written Nucala and SB-240563.
How each study uses mepolizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mepolizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 4 Nov 2015 · NUCALA · BLA 125526 (FDA, Drugs@FDA)
- European Union
- 1 Dec 2015 · Nucala · EMEA/H/C/003860 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
66 studies that test it; most in 2017 (7)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 7 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 32 · Other 34
GlaxoSmithKline (31) · Instituto de Investigación Marqués de Valdecilla (2) · McMaster University (2) · Mayo Clinic (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · St. Paul's Sinus Centre (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Rigshospitalet, Denmark (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Mepolizumab is the comparator. A study of two new drugs counts under both.
- 1Benralizumab · AstraZeneca
- 1SHR-1703 · Guangdong Hengrui Pharmaceutical Co., Ltd · next primary completion Dec 2028
Reaching primary completion within a year · 3
Studies that test mepolizumab.
- Dec 2026Identifying Predictors Of Response To Mepolizumab In CRSwNPPhase 4 · Centre hospitalier de l'Université de Montréal (CHUM)
- Dec 2026Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).Phase 4 · Instituto de Investigación Marqués de Valdecilla
- Jan 2027Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.Phase 4 · Instituto de Investigación Marqués de Valdecilla
Studies
Open first, then newest update. How each study uses mepolizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 66
- Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).RecruitingPhase 4Instituto de Investigación Marqués de ValdecillaNCT07814924Written as Mepolizumab 100 MGHow we know
- Airway Dysfunction, Occlusions and Remodeling: COPD Patients and MepolizumabNot yet recruitingPhase 4Western University, CanadaNCT07749001Written as Mepolizumab 100 MG InjectionHow we know
- Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPAEnrolling by invitationPhase 4Azienda Ospedaliero Universitaria di CagliariNCT07343661Written as Mepolizumab 100 MG Injection [Nucala]How we know
- th2 Modulation CRSwNPNot yet recruitingPhase 4St. Paul's Sinus CentreNCT06107101Written as MepolizumabHow we know
- Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab TreatmentRecruitingPhase 4St. Paul's Sinus CentreNCT05642806Written as MepolizumabHow we know
- Immunological Basis for Mepolizumab Activity in COPDNot yet recruitingPhase 2Temple UniversityNCT05320939Written as Mepolizumab 100 MGHow we know
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive StudyActive, not recruitingPhase 4GlaxoSmithKlineNCT06041386Written as MepolizumabHow we know
- Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.Active, not recruitingPhase 4Instituto de Investigación Marqués de ValdecillaNCT05923047Written as MepolizumabHow we know
- Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)CompletedPhase 3Assistance Publique - Hôpitaux de ParisNCT05030155Written as MepolizumabHow we know
- Identifying Predictors Of Response To Mepolizumab In CRSwNPActive, not recruitingPhase 4Centre hospitalier de l'Université de Montréal (CHUM)NCT05902325Written as Mepolizumab 100 MG InjectionHow we know
- Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelCompletedPhase 3GlaxoSmithKlineNCT04133909Written as MepolizumabHow we know
- Effect of Mepolizumab in Severe Bilateral Nasal PolypsCompletedPhase 3GlaxoSmithKlineNCT03085797Written as MepolizumabHow we know
- Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)CompletedPhase 3GlaxoSmithKlineNCT04607005Written as MepolizumabHow we know
- The Role of IL5 in Epithelial Cell IntegrityCompletedEarly Phase 1Johns Hopkins UniversityNCT05895929Written as MepolizumabHow we know
- Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)CompletedPhase 3GlaxoSmithKlineNCT04965636Written as MepolizumabHow we know
- A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPDCompletedPhase 3Sheffield Teaching Hospitals NHS Foundation TrustNCT05138250Written as Mepolizumab 100 MGHow we know
- Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic TrialCompletedPhase 2/3University of LeicesterNCT04075331Written as MepolizumabHow we know
- Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)CompletedPhase 4Helsinki University Central HospitalNCT04823585Written as MepolizumabHow we know
- Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic BronchitisCompletedPhase 3McMaster UniversityNCT01463644Written as MepolizumabHow we know
- Mepolizumab for the Treatment of Chronic Cough With Eosinophilic Airways DiseasesCompletedPhase 4McMaster UniversityNCT04765722Written as MepolizumabHow we know
See all 66 studies that test mepolizumab →
Given beside what is tested · 2 — mepolizumab is usual care or a partner of the new treatment
- Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNPNot yet recruitingPhase 4Eye & ENT Hospital of Fudan UniversityNCT07200336Written as MepolizumabHow we know
- Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 WeeksActive, not recruitingPhase 4Vibeke BackerNCT05598814Written as Mepolizumab InjectionHow we know
As the comparator · 6 — what is tested is compared with mepolizumab
- Complete Remission After Treatment With Biologics for Nasal PolypsRecruitingPhase 4Rigshospitalet, DenmarkNCT07268313Written as NUCALA®How we know
- A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis (EGPA)RecruitingPhase 2/3Guangdong Hengrui Pharmaceutical Co., LtdNCT05979051Written as Mepolizumab InjectionHow we know
- Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)CompletedPhase 3GlaxoSmithKlineNCT05263934Written as MepolizumabHow we know
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.Active, not recruitingPhase 3AstraZenecaNCT04157348Written as MepolizumabHow we know
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypeCompletedPhase 3GlaxoSmithKlineNCT04718389Written as MepolizumabHow we know
- Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male VolunteersStatus unknownEarly Phase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05353179Written as NUCALA®How we know
Codes
What other systems call mepolizumab · ClinicalTrials.gg INT004376
- MeSH (NLM) C434107mepolizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 90Z2UF0E52MEPOLIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1720597Confirmed FDA, Wikidata
- Wikidata Q3306175mepolizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C157376MepolizumabOne source FDA
- DrugBank DB06612One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C434107 | mepolizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 90Z2UF0E52 | MEPOLIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1720597 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3306175 | mepolizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C157376 | Mepolizumab | One source FDA |
| DrugBank | DB06612 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.